Pliant Therapeutics Q1 FY26 net loss narrows to $20 million

Pliant Therapeutics

Pliant Therapeutics

PLRX

0.00
  • Pliant Therapeutics posted a first-quarter net loss of $20 million, narrowing from $56.2 million a year earlier; loss per share improved to $0.32 from $0.92.
  • R&D expense dropped 68.71% to $13.6 million, while G&A expense fell 47.23% to $8.2 million.
  • Cash, cash equivalents and short-term investments totaled $172.4 million as of March 31, expected to fund operations into second half of 2028.
  • First participant was dosed in April in FORTIFY, a Phase 1b indication expansion trial of PLN-101095, with interim data expected in 2027.
  • AACR 2026 oral presentation highlighted updated Phase 1 PLN-101095 data showing one confirmed complete response and two confirmed partial responses in checkpoint inhibitor-refractory solid tumors.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pliant Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605111605PRIMZONEFULLFEED9717626) on May 11, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.